- Aptamer Group
- 18 August 2025 10:30:40
Source: Sharecast
Aptamer stated that following the successful completion of a project for the development of Optimer binders to support an ELISA assay, it has now secured an extension to this project.
The AIM-listed group said the paid-for extension involves the conversion of these binders into a fully functional ELISA assay, notingn that the progression demonstrated the efficacy of its Optimer technology in meeting the partner's requirements.
Aptamer said it retains ownership of the intellectual property associated with the binders, positioning it to potentially establish commercialisation licenses in the future. It also stated that the extension underscored its ability to deliver "high-quality results".
Chief executive Dr Arron Tolley said: "We are delighted to have successfully completed the initial binder development phase for this top five pharma partner and to now extend our collaboration into assay conversion.
"This milestone not only validates the performance of our Optimer platform but also highlights its potential for broader applications in diagnostics and therapeutics. Retaining IP ownership provides us with opportunities for future licensing revenues, aligning with our strategy to build long-term value through repeat business and commercialisation pathways."
As of 1030 BST, Aptamer shares had shot up 11.97% to 0.77p.
Reporting by Iain Gilbert at Sharecast.com
